CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 80 enrolled
Drug / intervention
Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04542616
NCT04542616N/ACompleted
CompareCT.gov

Outcomes Comparison Between Baerveldt 350 and Ahmed ClearPath 250 Tube Shunts for the Treatment of Glaucoma

State University of New York at Buffalo·interventional·Posted Sep 9, 2020·Updated Apr 17, 2026

In Brief

A clinical study evaluating Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for Glaucoma. Completed, enrolled 80 participants across 1 site.

Detailed Summary

To compare the safety and efficacy of Baerveldt 350 and Ahmed ClearPath 250 tube shunts in lowering IOP in glaucoma patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedSep 9, 2020
Enrollment StartAug 13, 2020
Primary CompletionJul 31, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 5.8 years ago

Interventions

Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantationdevice

Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.